UBT251: what it is and what the studies show

The compound was developed by United Bio-Technology (Hengqin), a subsidiary of The United Laboratories. According to a joint announcement by the companies (24 Mar 2025, company announcement), Novo Nordisk licensed the rights outside mainland China, Hong Kong, Macau and Taiwan, with US$200 million upfront and potential milestones of up to US$1.8 billion. At Novo Nordisk it carries the code NN-9559.

A long-acting synthetic peptide, injected once weekly, subcutaneously.

It acts on three receptors at once: GLP-1, GIP and glucagon. The first two relate to satiety and blood-sugar regulation. The third relates to energy expenditure.

An important gap: the company has not published the amino-acid sequence or the molecular weight — not in the scientific papers, not in its announcements. So no public source confirms its structure.

Fourteen clinical trials are registered. The picture splits cleanly in two:

In China, United Bio-Technology runs the Phase 3 trials. Of these, only the two in type 2 diabetes have begun recruiting (UNIGUIDE-1 and -2, 360 and 956 participants). The Phase 3 trials in obesity and sleep apnoea are registered but not yet recruiting, per the registry on 14 Oct 2026.

Outside China, Novo Nordisk runs the Phase 1 and 2 programme across the US, Canada, Australia, Germany, Spain, Poland, Hungary, Romania, Slovakia and South Korea.

Phase 2 trials in chronic kidney disease (NCT07134335) and steatohepatitis (NCT07145151) are also running.

Obesity, 24 weeks — peer-reviewed (Cell Metabolism, October 2026, PMID 42843337). Among 205 adults without diabetes, body-weight change ranged from −19.7% to −13.6% depending on dose, versus −2.0% on placebo. Placebo-adjusted, the difference was −17.7% to −11.5%. Changes were also reported in waist circumference, blood pressure and lipid profile. The mapping of the percentages to doses is not in the paper's abstract and we do not give it.

Early trial, 12 weeks — peer-reviewed (Diabetes Obes Metab, September 2026, PMID 42712041). In participants with overweight or obesity without diabetes, at 1, 3 and 6 mg weekly, mean weight reduction was 8.96 to 13.48 kg depending on dose (the per-dose mapping is not in the abstract), while the placebo group gained 1.57 kg.

Type 2 diabetes, 24 weeks — company announcement only (25 Mar 2026), not published. Among 211 Chinese patients, a reduction in glycated haemoglobin of up to 2.16% was reported, from a baseline of 8.12%. The company promised detailed data at a congress; we did not find it published.

Clinical-trial facts, not usage instructions. UBT251 is an investigational compound without approval.

Phase 2 and 3 trials used three doses, once weekly subcutaneously: 2.0 mg, 4.0 mg and 6.0 mg. The 4.0 mg arms record a starting dose of 0.5 or 1.0 mg. Early trials tested single doses from 0.1 to 4.5 mg, and weekly doses of 1, 3 and 6 mg for 12 weeks.

The step-up intervals are not published in any registry record we checked.

According to the abstracts of the two published studies, the most frequent adverse events were gastrointestinal, mild to moderate, along with decreased appetite.

Per-dose rates have not been published. The registries have posted no results and the abstracts of the papers do not contain them. Figures circulating on blogs are not reproduced here.

Trials excluded people with a history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, pancreatitis, kidney function below a threshold, retinal disease, gastroparesis, and those pregnant or breastfeeding.

• Its structure. Sequence, length and molecular weight are unpublished.
• Its half-life. A figure appears in a stock-exchange filing, but we could not open the original. We do not publish it.
• Adverse-event rates per dose.
• Detailed diabetes data, which remain a company announcement.

This content is educational and research-oriented. UBT251 is an investigational compound, is not approved as a medicine, and is not intended for human use. This is not medical advice.